Log in
Enquire now
‌

US Patent 10246482 Neuroactive steroids, compositions, and uses thereof

Patent 10246482 was granted and assigned to SAGE Therapeutics on April, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
Current Assignee
SAGE Therapeutics
SAGE Therapeutics
Date Filed
June 18, 2015
Date of Patent
April 2, 2019
Patent Applicant
SAGE Therapeutics
SAGE Therapeutics
Patent Application Number
15319503
Patent Citations Received
‌
US Patent 12083131 Neuroactive steroids, compositions, and uses thereof
0
‌
US Patent 12065463 Compositions and methods for treating CNS disorders
0
‌
US Patent 12071453 Neuroactive steroids, compositions, and uses thereof
0
‌
US Patent 11498940 Neuroactive steroids, compositions, and uses thereof
‌
US Patent 10426837 Compositions and methods for treating CNS disorders
‌
US Patent 10435431 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
‌
US Patent 10577390 Compositions and methods for treating CNS disorders
‌
US Patent 11530237 Compositions and methods for treating CNS disorders
‌
US Patent 11236121 Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
‌
US Patent 11542297 Compositions and methods for treating CNS disorders
•••
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10246482
Patent Primary Examiner
‌
Pancham Bakshi

Find more entities like US Patent 10246482 Neuroactive steroids, compositions, and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us